SG11202007381YA - Novel small molecule drug conjugates of gemcitabine derivatives - Google Patents

Novel small molecule drug conjugates of gemcitabine derivatives

Info

Publication number
SG11202007381YA
SG11202007381YA SG11202007381YA SG11202007381YA SG11202007381YA SG 11202007381Y A SG11202007381Y A SG 11202007381YA SG 11202007381Y A SG11202007381Y A SG 11202007381YA SG 11202007381Y A SG11202007381Y A SG 11202007381YA SG 11202007381Y A SG11202007381Y A SG 11202007381YA
Authority
SG
Singapore
Prior art keywords
small molecule
drug conjugates
molecule drug
novel small
gemcitabine derivatives
Prior art date
Application number
SG11202007381YA
Other languages
English (en)
Inventor
Steven Albert Everett
Craig Alan Coburn
Original Assignee
Maverix Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maverix Oncology Inc filed Critical Maverix Oncology Inc
Publication of SG11202007381YA publication Critical patent/SG11202007381YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90245—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/24—Post-translational modifications [PTMs] in chemical analysis of biological material hydroxylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SG11202007381YA 2018-02-02 2019-02-04 Novel small molecule drug conjugates of gemcitabine derivatives SG11202007381YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862625779P 2018-02-02 2018-02-02
PCT/US2019/016477 WO2019152911A1 (en) 2018-02-02 2019-02-04 Novel small molecule drug conjugates of gemcitabine derivatives

Publications (1)

Publication Number Publication Date
SG11202007381YA true SG11202007381YA (en) 2020-08-28

Family

ID=65494546

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202007381YA SG11202007381YA (en) 2018-02-02 2019-02-04 Novel small molecule drug conjugates of gemcitabine derivatives

Country Status (13)

Country Link
US (1) US20210380626A1 (cg-RX-API-DMAC7.html)
EP (1) EP3746133A1 (cg-RX-API-DMAC7.html)
JP (3) JP2021512951A (cg-RX-API-DMAC7.html)
KR (1) KR20200118828A (cg-RX-API-DMAC7.html)
CN (1) CN112135635A (cg-RX-API-DMAC7.html)
AU (1) AU2019216514A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020015747A2 (cg-RX-API-DMAC7.html)
CA (1) CA3090272A1 (cg-RX-API-DMAC7.html)
EA (1) EA202091857A1 (cg-RX-API-DMAC7.html)
IL (1) IL276442A (cg-RX-API-DMAC7.html)
PH (1) PH12020551178A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202007381YA (cg-RX-API-DMAC7.html)
WO (1) WO2019152911A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200118827A (ko) * 2018-02-02 2020-10-16 마베릭스 온콜로지, 잉크. 젬시타빈 모노포스페이트의 소분자 약물 컨쥬게이트
CN114349816B (zh) * 2021-11-30 2024-08-30 潍坊博创国际生物医药研究院 一种基于氨肽酶n/cd13的小分子偶联分子及其制备方法和应用
WO2026009986A1 (ja) * 2024-07-05 2026-01-08 学校法人東京理科大学 化合物の製造方法及び化合物
WO2026009987A1 (ja) * 2024-07-05 2026-01-08 学校法人東京理科大学 化合物の製造方法、化合物、及びヌクレオチドプロドラッグ前駆体
CN119708099B (zh) * 2024-12-23 2025-10-24 中国药科大学 吉西他滨前药及其医药用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2319837C (en) 1998-02-12 2009-10-27 De Montfort University Hydroxylation activated drug release
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
GB0907551D0 (en) * 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
EP3078671A4 (en) * 2013-12-04 2017-05-31 Hangzhou Minsheng Institutes for Pharma Research Co., Ltd. Gemcitabine derivative, composition containing the derivative and pharmaceutical use of the derivative
WO2015134334A1 (en) * 2014-03-03 2015-09-11 Suo Zucai Gemcitabine analogs
CN105001291B (zh) * 2014-04-15 2018-12-04 上海知萌生物医药科技有限公司 吉西他滨化学传递前药及其制备方法和应用
CN107295800A (zh) * 2015-02-25 2017-10-24 配体药物公司 吉西他滨衍生物

Also Published As

Publication number Publication date
JP2026090362A (ja) 2026-06-02
PH12020551178A1 (en) 2021-06-07
EA202091857A1 (ru) 2020-12-04
JP2021512951A (ja) 2021-05-20
JP2024073414A (ja) 2024-05-29
CA3090272A1 (en) 2019-08-08
US20210380626A1 (en) 2021-12-09
BR112020015747A2 (pt) 2020-12-08
EP3746133A1 (en) 2020-12-09
AU2019216514A1 (en) 2020-09-24
IL276442A (en) 2020-09-30
KR20200118828A (ko) 2020-10-16
CN112135635A (zh) 2020-12-25
WO2019152911A1 (en) 2019-08-08

Similar Documents

Publication Publication Date Title
HUE071437T2 (hu) Ciklikus dinukleotid-származékok antitest-hatóanyag konjugátumjai
IL276442A (en) New small molecule drug conjugates of gemcitabine history
PL3958977T3 (pl) Pochodne kamptotecyny
DK3870234T3 (da) Antistoflægemiddelkonjugater omfattende ecteinascidinderivater
EP3690038A4 (en) ANTIBODY PYRROLOBENZODIACEPINE DERIVATIVE CONJUGATE
EP3749357A4 (en) POLYVALENT PNEUMOCOCCAL POLYSACCHARIDE PROTEIN CONJUGATE COMPOSITION
MX389728B (es) Conjugados de farmacos proteinas de union que comprenden derivados de antraciclina.
DK3655017T3 (da) Farmaceutisk sammensætning
PT3790874T (pt) Derivados de quinolina antelmínticos
IL271859A (en) Continuous production of drug molecule conjugates for guidance
IL273528A (en) Long-term conjugates of GLP-2 derivatives
IL270979A (en) Pharmaceutical formulations for small molecules that are resistant to sedimentation
EP3600341A4 (en) GEMCITA BIN DERIVATIVES FOR CANCER THERAPY
DK3583943T3 (da) Farmaceutisk sammensætning
EP3634492A4 (en) HIGH THROUGHPUT SYNTHESIS OF BIOMOLECULAR POLYMER CONJUGATES
SI3573948T1 (sl) Postopki za pripravo citotoksičnih derivatov benzodiazepina
EP3986939A4 (en) TWO-DRUG ANTIBODY-DRUG CONJUGATE
DK3666787T3 (da) Antistoflægemiddelkonjugater som inkluderer hemiasterlinderivat
EP3706731A4 (en) IMPROVED DRUG FORMULATIONS
LT4056557T (lt) Benzazepino dariniai, naudotini kaip vaistai
SMT202400478T1 (it) Composizione farmaceutica
IL276436A (en) Gemcitabine monophosphate small molecule drug conjugates
HK40042807A (en) Novel small molecule drug conjugates of gemcitabine derivatives
HK40042806A (en) Small molecule drug conjugates of gemcitabine monophosphate
EP3589372A4 (en) CHEMOTHERAPEUTIC COMPOSITION